Drug maker, Ranbaxy Laboratories has received an approval from the Therapeutic Goods Administration (TGA), Department of Health and Ageing, of the Australian Government for the registration of SEBIFIN Terbinafine tablets in Australia.

The approval was based on the assessment by the TGA that Ranbaxy (Q, N,C,F)* formulation of Terbinafine is bioequivalent to, and having the same therapeutic effect as that of the reference listed product, Lamisil tablets of Novartis Pharmaceutical Australia (P).

With the approval of SEBIFIN, the drug maker now has a total number of 26 molecules approved for marketing in Australia since the incorporation of Ranbaxy Australia in 2004.

Shares of the company declined Rs 3.7, or 2.56%, to trade at Rs 140.70. The total volume of shares traded was 1,904,299 at the BSE (2.35 p.m., Friday).